Peer Review History: Efficacy and Side Effects of Generic (Osloda®) and Brand-Name (Xeloda®) Capecitabine in Metastatic Breast Cancer

Open Peer Review Policy: Click Here

Specific Comment:

Average Peer review marks at initial stage: 8.7/10

Average Peer review marks at publication stage: 9/10

Peer Review History:

Stage 1 | Original Manuscript | File 1 | NA

Stage 2 | Peer review report_1 (Anubha Bajaj, India) | File 1 | NA

Stage 2 | Peer review report_2 (Santoshi Muppala, USA) | File 1 | NA

Stage 2 | Peer review report_3 (Tagne Simo Richard, Cameroon) | File 1 | NA

Stage 2 | Peer review report_4 (Kenan Adnan Aloss, Syria) | File 1 | NA

Stage 2 | Peer review report_5 (Ahamefule, Augustus Kelechi, Nigeria) | File 1 | File 2

Stage 2 | Revised_MS_v1_and_Feedback_v1 | File 1 | File 2

Stage 3 | Comment_Editor_1_v1 | File 1 | NA

Stage 3 | Comment_Editor_2_v1 | File 1 | NA